Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Filings indexed 359 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Informacja Zarządu w sprawie wyboru firmy audytorskiej
Regulatory Filings
2026-04-30 Polish
Sprawozdanie z działalności 2025 - podpis
Regulatory Filings
2026-04-30 Polish
Sprawozdanie z działalności 2025
Regulatory Filings
2026-04-30 Polish
Sprawozdanie finansowe 2025 - podpis
Regulatory Filings
2026-04-30 Polish
Sprawozdanie finansowe 2025
Regulatory Filings
2026-04-30 Polish
List Prezesa Zarządu 2025 - podpis
Regulatory Filings
2026-04-30 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.